Elotuzumab is a monoclonal antibody that specifically targets the SLAMF7 receptor. While it demonstrates minimal antimyeloma activity as a monotherapy in cases of relapsed or refractory multiple myeloma (RRMM), its efficacy is significantly enhanced when used in conjunction with other antimyeloma agents. This combination therapy has been shown to improve both response rates and overall outcomes in multiple myeloma treatment.
Elotuzumab is a monoclonal antibody that specifically targets the SLAMF7 receptor. While it demonstrates minimal antimyeloma activity as a monotherapy in cases of relapsed or refractory multiple myeloma (RRMM), its efficacy is significantly enhanced when used in conjunction with other antimyeloma agents. This combination therapy has been shown to improve both response rates and overall outcomes in multiple myeloma treatment.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
